Chemotherapeutic Activity of Imidazolium-Supported Pd(II) <i>o</i>-Vanillylidene Diaminocyclohexane Complexes Immobilized in Nanolipid as Inhibitors for HER2/neu and FGFR2/FGF2 Axis Overexpression in Breast Cancer Cells.

Pharmaceuticals (Basel) · 2023 · PMC10747766 · PMID 38139837

Europe PMC DOI

hedged sentence

0.0001

closest p · 0.0× alpha

0.0001

boldest claim

The sentences

highly significantp -value < 0.0001actually significant

Moreover, Pd 1,2 LNP revealed a highly significant drop for the Her2/neu quantitative expression in the MCF7 treated cells with a p -value < 0.0001 compared to cisplatin and trastuzumab ( Figure 7 ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Chemotherapeutic Activity of Imidazolium-Supported Pd(II) &lt;i&gt;o&lt;/i&gt;-Vanillylidene Diaminocyclohexane Complexes Immobilized in Nanolipid as Inhibitors for HER2/neu and FGFR2/FGF2 Axis Overexpression in Breast Cancer Cells.

The sentences

Chemotherapeutic Activity of Imidazolium-Supported Pd(II) <i>o</i>-Vanillylidene Diaminocyclohexane Complexes Immobilized in Nanolipid as Inhibitors for HER2/neu and FGFR2/FGF2 Axis Overexpression in Breast Cancer Cells.